Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results

--Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same period in 2016----Ended the first quarter with a strong cash position of $434 million--CAMBRIDGE, Mass.,...
April 26, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference

CAMBRIDGE, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
April 18, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
February 28, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
February 21, 2017 07:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results

CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2016. ...
February 17, 2017 18:05 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its fourth quarter and year end 2016 earnings...
February 17, 2017 18:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer

Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues Warning letter does not restrict the production or shipment of Glatopa 20 mg CAMBRIDGE,...
February 17, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL

CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
February 07, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
February 01, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the Leerink Partners 6th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right